Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-307 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals. Research supp...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 28, 2019 Category: Research Source Type: funding
Postdoctoral Research Associate Training (PRAT) Program (Fi2)
Funding Opportunity PAR-19-286 from the NIH Guide for Grants and Contracts. The NIGMS Postdoctoral Research Associate Training (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of postdoctoral fellows in NIH Intramural research laboratories, and to prepare them for leadership positions in biomedical careers. Research projects proposed should focus on areas within the NIGMS mission, which include but are not limited to biological chemistry, biophysics, bioinformatics, cellular and molecular biology, computational biosciences, dev...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 21, 2019 Category: Research Source Type: funding
Sample Grant Applications, Summary Statements, and More
If you are new to writing grant applications, sometimes seeing how someone else has presented their idea can help as you are developing your own application. With the gracious permission of successful investigators, the National Institute of Allergy and Infectious Diseases (NIAID) makes available examples of funded R01, R03, R15, R21, SBIR/STTR, K, and F applications, summary statements, sharing plans, leadership plans, and more. When referencing these resources, it is important to remember:
These applications were developed using the application forms and instructions that were in effect at the time of their submission...
Source: NIH Extramural Nexus - May 1, 2019 Category: Research Authors: NIH Staff Tags: Tips Before You Submit grant tips sample application Source Type: funding
Notice of Change in Expiration Date of PAR-19-229 "Informatics Methodology and Secondary Analyses for Immunology Data in ImmPort (UH2 Clinical Trial Not Allowed)"
Notice NOT-AI-19-055 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 8, 2019 Category: Research Source Type: funding
Informatics Methodology and Secondary Analyses for Immunology Data in ImmPort (UH2 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-229 from the NIH Guide for Grants and Contracts. The goals of this Funding Opportunity Announcement (FOA) are to support the development of new or improved informatics tools and methods for the reuse of shared data in the immunology study repository, ImmPort; and to support secondary analyses of existing immunology datasets to address basic and clinical immunology questions. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 22, 2019 Category: Research Source Type: funding
Emerging Infectious Diseases Research Centers (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish a coordinated network of Emerging Infectious Disease Research Centers (EIDRCs) in regions around the globe where emerging and re-emerging infectious disease outbreaks are likely to occur. Multidisciplinary teams of investigators will conduct pathogen/host surveillance, study pathogen transmission, pathogenesis and immunologic responses in the host, and will develop reagents and diagnostic assays for improved detection for important emerging pathogens and their vectors....
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 5, 2019 Category: Research Source Type: funding
Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)
Funding Opportunity PA-19-201 from the NIH Guide for Grants and Contracts. The purpose of this FOAs are to encourage mechanistic research to investigate the impact of sleep disturbances on chronic pain. The mechanisms and processes underlying the contribution of sleep disturbances to chronic pain development and maintenance may be very broad. This FOA encourages interdisciplinary collaborations by experts from multiple fieldsneuroscientists, psychologists,endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of in...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 28, 2019 Category: Research Source Type: funding
Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)
Funding Opportunity PA-19-200 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fieldsneuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 28, 2019 Category: Research Source Type: funding
Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-194 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 22, 2019 Category: Research Source Type: funding
Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-193 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 22, 2019 Category: Research Source Type: funding
Request for Information (RFI): Immunologic Assays for Identifying Correlates of Protection (COP) Against Congenital Cytomegalovirus Transmission and/or Disease
Notice NOT-AI-19-035 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 7, 2019 Category: Research Source Type: funding
Computational Models of Immunity (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications developing computational models of immunity that advance understanding of the mechanisms required to induce and/or maintain protective immunity to infectious pathogens, other than HIV, and/or vaccines against such pathogens. The main goal of this FOA is to advance development and application of computational models of immunity that are refined through iterative immunological experimentation to validate and improve the utility and robustness of the computational models. Another ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 30, 2019 Category: Research Source Type: funding
Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional)
Funding Opportunity RFA-AT-19-009 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 3, 2019 Category: Research Source Type: funding
Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R01 Clinical Trial Optional)
Funding Opportunity RFA-AT-19-008 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 3, 2019 Category: Research Source Type: funding
U.S.-Brazil Collaborative Biomedical Research Program (R01 Clinical Trial Optional)
Funding Opportunity RFA-AI-18-054 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote collaborative biomedical research between the United States and Brazil under the U.S.-Brazil Biomedical Collaborative Research Program. Research areas supported under this program include allergy, immunology, and infectious diseases, including HIV/AIDS and its co-morbidities; cancer; mother-to-child transmission of HIV and other congenital infections, early infant diagnosis and treatment; HIV/AIDS in relation to mental health; and neurological disorders and stroke. (Sour...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 4, 2018 Category: Research Source Type: funding
